Pfizer 4Q Revenues: $13.6 billion (-9%) 4Q Earnings: $2.7 billion (-3%) FY Revenues: $51.3 billion (-2%) FY Earnings: $8.1 billion (-29%) Comments: Human Health revenue declined 4% for the year due to U.S. generic competition for certain key medicines, uncertainty related to Celebrex, and the suspension of Bextra sales. Celebrex sales were down 53% to $472 million for the quarter. Lipitor sales were up 3% to $3.4 billion for the quarter, and up 12% to $12.2 billion for the yea...